• This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of the development and potential approval of Huxley's 3,4-Diaminopyridine product for the treatment of LEMS. (bio-medicine.org)
  • This enzyme catalyses the following chemical reaction Hydrolysis of the 4-sulfate groups of the N-acetyl-D-galactosamine 4-sulfate units of chondroitin sulfate and dermatan sulfate This enzyme also acts on N-acetylglucosamine 4-sulfate. (wikipedia.org)
  • The newer method uses a fluorogenic substrate, 4-methylumbelliferyl-â-D-galactose-6-sulphate. (sas-centre.org)
  • The enzyme acts upon this to release sulphate and 4mu-â-galactoside, which is then acted upon by â-galactosidase to produce galactose and 4-methylumbelliferone. (sas-centre.org)
  • Molecular Genetics and Metabolism, 94 (4), 469 - 475. (up.pt)
  • Scandinavian Journal of Clinical and Laboratory Investigation 4: 43-46. (els.net)
  • Diagnosis generally requires evidence of clinical picture, ASB activity of less than 10% of the lower limit of normal in cultured fibroblasts or isolated leukocytes , and demonstration of a normal activity of a different sulfatase enzyme (to exclude mucosulfatidosis, see this term). (cdc.gov)
  • Further research is needed to identify these iodothyronine sulfatases, and to study the physiological importance of the reversible sulfation of iodothyronines in thyroid hormone metabolism. (diff.org)
  • BMRN ) announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). (bio-medicine.org)
  • Journal of Pediatrics, 148 (4), 533 - 533.e. (up.pt)
  • Patients are evaluated with physical examinations and laboratory tests for blood and urine at Weeks 1, 2, 4, 6, 8, and 12 and two weeks post study. (bioportfolio.com)
  • Patients remain on study medications for 24 weeks and are seen at the clinic once every 4 weeks after entering the study. (bioportfolio.com)
  • Here, we used discovery-based proteomics to detect HLA-DR-presented peptides in synovia or peripheral blood mononuclear cells and identified 2 autoantigens, N -acetylglucosamine-6-sulfatase (GNS) and filamin A (FLNA), as targets of T and B cell responses in 52% and 56% of RA patients, respectively. (jci.org)
  • This medicine improves walking and stair-climbing ability in patients who are lacking a certain enzyme called N-acetylgalactosamine 4-sulfatase in the body. (adam.com)